Working… Menu
Trial record 1 of 8 for:    "Angiomyolipoma" | "Immunosuppressive Agents"
Previous Study | Return to List | Next Study

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02539459
Recruitment Status : Terminated (Extreme toxicity, met toxicity stopping rules)
First Posted : September 3, 2015
Last Update Posted : September 17, 2018
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : August 20, 2018
Actual Study Completion Date : August 20, 2018